tumors may benefit more than HER2+/HR+ tumors from dual HER2 blockade, according to 5-year results from the phase III ALTTO trial. The Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation study, or ALTTO, is an international phase III clinical trial of two targeted. Background: Pre-specified 5-year analyses of the phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation (ALTTO) Trial.

Author: Kell JoJojinn
Country: Bolivia
Language: English (Spanish)
Genre: Education
Published (Last): 25 January 2018
Pages: 418
PDF File Size: 18.34 Mb
ePub File Size: 12.19 Mb
ISBN: 671-5-65085-747-3
Downloads: 20881
Price: Free* [*Free Regsitration Required]
Uploader: Grokus

Lapatinib is another drug developed to wltto HER2-positive breast cancer. HER2-positive breast cancers are usually treated with trastuzumab, which has been shown to lower the rate of cancer recurrence and improve survival when given with chemotherapy. Breast Cancer Res Treat Patients with a prior malignancy diagnosed greater than 10 years in the past who have been curatively treated with surgery ONLY, WITHOUT radiation therapy or systemic therapy chemotherapy or endocrine are eligible for the study.

By Caroline Helwick June 10, Advertisement. As the discussant of this paper at the Plenary Session, George W.

Jumping higher: is it still possible? The ALTTO trial challenge.

Citing articles via Google Scholar. It also assessed the safety of lapatinib and triao to identify specific molecular markers indicators found in blood or other human tissue to predict which patients will benefit most from lapatinib or trastuzumab.

Meta-analysis of individual patient data for 10 women in 17 randomized trials.


The analysis by hormone receptor status was similar. Locoregional recurrence following frial cancer surgery in the trastuzumab era: Analysis of regional timelines to set up a global phase III clinical trial in breast cancer: In view of this, the ALTTO trial was set up is to explore if lapatinib is also effective in patients with early disease who are given an adjuvant therapy treatment given after surgery. GlaxoSmithKline GSK was the sponsor and funder of the study until 30 Novafter rrial these responsibilities were transferred to Novartis.

Close mobile search navigation Article navigation. This study is in progress, not grial new patients. The current efficacy results were based on 6, patients randomized. It works inside the cells to slow or stop the processes that cause tumour growth and disease progression. After surgery and a standard treatment with chemotherapy, patients enrolled in ALTTO were randomly assigned to receive one of these four treatments for a period altho 1 year: Non-anthracycline platinum containing regimen docetaxel and carboplatin and study treatment must start concomitantly and no more than 14 days after randomisation.

A protocol-specified updated efficacy analysis is planned in 2 years. For the disease-free survival noninferiority analysis, the hazard ratio was 0.

ALTTO Trial Finds Dual Anti-HER2 Therapy No Better Than Trastuzumab Alone – The ASCO Post

Regional nodal irradiation after breast-conserving surgery for early HER2-positive breast cancer: See also Companion Articles Response. Given all of these points, we have doubts about the conclusions of frial ALTTO-retrospective findings for obvious reasons: Secondary objectives include treatment comparisons with respect to overall survival, time to recurrence, time to distant recurrence, safety and tolerability, incidence of brain metastasis, and analyses conducted separately for cohorts of patients defined by presence or absence of cMyc oncogene amplification, expression level of PTEN and presence or absence of the p95HER2 receptor.


This is not standard of care and is probably related to different practices in the participating countries.

Email alerts New issue alert. As RNI clearly contributes tria, improving distant metastasis—free survival DMFS 23it is unclear why these rules, widely accepted in all BC patients, would be unsuitable for the more aggressive HER2-positive disease. At a median follow-up of 4.

You CAN’T join if Patients with hormone receptor—positive cancers also received appropriate hormonal therapy. When the study was designed, it was thought that using both drugs combined or in sequence might work better than giving either drug alone.

Perez emphasized that failure to meet the primary endpoint—improved outcomes with dual HER2 blockade—was unexpected. Receive exclusive offers and updates from Oxford Academic. Presented June 1, Sign In or Create an Account.

In addition alttto the coordinating partners, 19 academic research groups from the BIG network are participating in this study.

Piccart-Gebhart noted in her presentation.